<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234481</url>
  </required_header>
  <id_info>
    <org_study_id>XL844-001</org_study_id>
    <nct_id>NCT00234481</nct_id>
  </id_info>
  <brief_title>Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exelixis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of different doses of&#xD;
      XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia&#xD;
      or small lymphocytic lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed due to slow enrollment&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XL844</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small&#xD;
             lymphocytic lymphoma (SLL)&#xD;
&#xD;
          -  Prior treatment with at least 2 systemic chemotherapy regimens for CLL&#xD;
&#xD;
          -  Life expectancy of &gt;3 months&#xD;
&#xD;
          -  Adequate liver and kidney function&#xD;
&#xD;
          -  Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL&#xD;
&#xD;
          -  Willing to use accepted method of contraception during the course of the study&#xD;
&#xD;
          -  Negative pregnancy test (females)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on&#xD;
             the therapy)&#xD;
&#xD;
          -  Investigational drug within 30 days of the start of treatment&#xD;
&#xD;
          -  Uncontrolled intercurrent illness such as infection or cardiovascular disease&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Subjects known to be HIV positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope National Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>October 5, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2005</study_first_posted>
  <last_update_submitted>June 2, 2008</last_update_submitted>
  <last_update_submitted_qc>June 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

